AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAIA
  4. [8-K] MAIA Biotechnology, Inc. Reports Material Event

[8-K] MAIA Biotechnology, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source:

Stock MAIA logo
MAIA Biotechnology Inc.

NYSE:MAIA

MAIA Rankings

#7578 Ranked by Market Cap
N/A Ranked by Dividends

MAIA Latest News

Jul 17, 2025
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
Jul 9, 2025
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
Jul 1, 2025
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
Jun 24, 2025
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
Jun 18, 2025
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

MAIA Latest SEC Filings

Jul 9, 2025
[8-K] MAIA Biotechnology, Inc. Reports Material Event
Jul 2, 2025
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity
Jul 2, 2025
[Form 4] MAIA Biotechnology, Inc. Insider Trading Activity

MAIA Stock Data

61.85M
23.22M
26.41%
5.29%
3.29%
Biotechnology
Pharmaceutical Preparations
United States
CHICAGO